The revenue was flat when compared with the same period last year and net income was down 30 percent. The Symmetry Surgical segment revenue decreased 18.2 percent during the second quarter due primarily to ongoing recovery from transition-related sales disruptions with certain U.S. customers
More Articles on Orthopedic and Spine Devices:
Lanx Publishes Favorable Study for ASPEN Minimally Invasive Spinal Fusion Device
Integra LifeSciences Receives FDA Clearance for Titan Reverse Shoulder System
DJO Global Posts $20.6M Net Loss in Q2
